Abstract
The introduction of imatinib has radically altered the treatment options and, perhaps, prognosis for patients with newly diagnosed chronic myelogenous leukemia (CML). However, although the majority of patients appear to benefit from this agent, it is important to recognize as early as possible the patients who experience a suboptimal response and those who may be at risk of disease progression. This article reviews current available methods of monitoring and provides recommendations for appropriate follow up of imatinib-treated patients.
| Original language | English |
|---|---|
| Pages (from-to) | 513-517 |
| Number of pages | 5 |
| Journal | JNCCN Journal of the National Comprehensive Cancer Network |
| Volume | 1 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 1 Nov 2003 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Chronic myelogenous leukemia
- Cytogenetics
- FISH
- Imatinib
- Monitoring
- PCR
Fingerprint
Dive into the research topics of 'How to monitor patients with chronic myelogenous Leukemia'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver